Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81%
The COVID-19 Treatment Guidelines Panel’s Statement on the Emergency Use Authorization of Anti-SARS-CoV-2 Monoclonal Antibodies for the Treatment of COVID-19 Last Updated: April 8, 2021
諦めだよ。残念だが。 0985名無しさん@お腹いっぱい。2021/04/19(月) 19:56:21.07 Novartis inks 3rd COVID-19 production pact, this time for Roche's arthritis med Actemra Apr 15, 2021 10:30am